Dengue Treatment Drug Interactions Clinicians Should Know
Why NSAIDs, aspirin and antiplatelet drugs are contraindicated in dengue, per MoHFW's national clinical guidelines, and what interacts with what.
This piece runs through the dengue treatment drug interactions that matter most, why each matters clinically, and closes on why a hospital's own pharmacy stocking and dispensing discipline is part of getting this right.
Why are NSAIDs and aspirin specifically contraindicated in dengue?
MoHFW's national dengue guideline explicitly states that aspirin and NSAIDs should be avoided in dengue fever because they can cause gastritis, vomiting, acidosis, and platelet dysfunction, recommending paracetamol as the preferred antipyretic and analgesic instead. Dengue itself frequently causes thrombocytopenia, and layering a drug class known to impair platelet function on top of an already falling platelet count compounds bleeding risk rather than simply adding a side effect.
This is the single most important interaction rule in dengue management, and it applies regardless of how mild the presenting fever looks, since the platelet trajectory over the following days is what actually determines risk, not the initial severity.
Does the evidence on NSAID bleeding risk in dengue actually support this restriction uniformly?
The clinical literature shows some nuance worth understanding. Several epidemiologic and cohort studies found minimal or no significant increase in bleeding risk from general NSAID use in dengue, with aspirin the agent most consistently linked to risk. Factors most strongly associated with actual bleeding risk were prior antiplatelet drug use and a platelet count below 70,000/µL.
This nuance does not change the guideline-level recommendation. National guidelines are written for population-level safety across all severity levels and all points in the disease course, and MoHFW's blanket avoidance of NSAIDs and aspirin remains the operative clinical standard regardless of what individual studies suggest about relative risk within the class.
What other drug interactions matter in dengue beyond NSAIDs?
Existing antiplatelet therapy (for a patient with prior cardiac stenting, for example) and anticoagulants both meaningfully raise bleeding risk when a patient develops dengue-related thrombocytopenia, and published research on temporary antiplatelet interruption during dengue with thrombocytopenia reflects how seriously this interaction is taken in practice. Corticosteroids and proton pump inhibitors have also been flagged in the literature as amplifying bleeding risk in combination with these other factors.
This means dengue management for a patient already on chronic antiplatelet or anticoagulant therapy is a genuinely more complex clinical decision than for a drug-naive patient, requiring case-by-case judgement on whether and how long to hold the existing therapy, not a fixed universal rule.
What antipyretic and fluid management interactions should a hospital pharmacy be aware of?
Paracetamol is the guideline-recommended antipyretic in dengue precisely because it lacks the antiplatelet and gastric-irritant properties of NSAIDs, making correct antipyretic stocking and dispensing a frontline safety measure, not just symptom control. A pharmacy that substitutes an NSAID-containing combination product for straightforward paracetamol, even inadvertently, works directly against the national guideline.
Beyond antipyretics, dengue management leans heavily on oral and IV fluid management rather than additional pharmacological agents in most non-severe cases, which is part of why correct triage and monitoring, not drug complexity, drives most dengue treatment decisions.
How do the main dengue-relevant drug interactions compare?
| Drug/class | Interaction risk in dengue | Guideline-recommended action |
|---|---|---|
| Aspirin | Platelet dysfunction, most consistently linked to bleeding risk | Avoid |
| NSAIDs (ibuprofen, etc.) | Gastritis, platelet dysfunction, acidosis | Avoid; use paracetamol instead |
| Existing antiplatelet therapy | Compounds bleeding risk with thrombocytopenia | Case-by-case reassessment with treating physician |
| Anticoagulants | Compounds bleeding risk with thrombocytopenia | Case-by-case reassessment with treating physician |
| Paracetamol | No platelet effect | Preferred antipyretic/analgesic |
This table reflects guideline-level risk classification; individual patient management always requires clinical judgement based on platelet trajectory and comorbidity.
Why does correct dengue drug stocking matter to a hospital's own pharmacy?
Dengue season drives sharp, predictable surges in demand for paracetamol specifically, and a hospital pharmacy that runs short during peak season risks patients or even ward staff reaching for an NSAID-containing alternative purely because it's what's available, working directly against the national guideline. Getting antipyretic stocking right during a dengue surge is a genuine patient-safety measure, not just an inventory exercise.
Medyzen's managed hospital pharmacy model is built to keep exactly this kind of seasonal, high-volume, safety-critical drug reliably in stock rather than forcing a substitution at the counter, and the broader cost of losing these prescriptions to an outside chemist is covered in prescription leakage and hospital revenue loss. The inventory forecasting that handles seasonal demand spikes like this without turning into dead stock off-season is covered in pharmacy inventory management.
Sources
- 1National Guidelines for Clinical Management of Dengue Fever 2023 — National Centre for Vector Borne Diseases Control, Ministry of Health and Family Welfare
- 2Guidelines on Clinical Management of DF/DHF/DSS — National Vector Borne Disease Control Programme, Government of India
- 3Symptomatic treatment of dengue: Should the NSAID contraindication be reconsidered? — Postgraduate Medicine, peer-reviewed
- 4Safety of temporary interruption of antiplatelet therapy in dengue fever with thrombocytopenia — International Journal of Infectious Diseases, peer-reviewed
- 5Bleeding in Antiplatelet Therapy: A Narrative Review of Clinical Evidence — National Institutes of Health, National Library of Medicine
This article is for informational purposes and is not a substitute for professional medical advice. Antipyretic and antiplatelet/anticoagulant management decisions in dengue must be individualised by the treating physician based on platelet count and clinical course.
FAQ
Frequently asked questions
Aspirin can cause platelet dysfunction and gastric irritation, both of which compound the bleeding risk already present from dengue-related thrombocytopenia, per MoHFW's national dengue guideline.
Yes, paracetamol is the guideline-recommended antipyretic and analgesic in dengue specifically because it does not carry the antiplatelet or gastric-irritant effects of NSAIDs and aspirin.
It requires case-by-case clinical management; existing antiplatelet or anticoagulant therapy compounds bleeding risk when combined with dengue-related thrombocytopenia, and continuation or temporary interruption is a decision for the treating physician.
Evidence suggests aspirin is most consistently linked to increased bleeding risk, with some studies finding minimal risk increase from general NSAID use; national guidelines nonetheless recommend avoiding the entire class as a precaution.
Careful fluid management and monitoring, rather than additional pharmacological agents, drives most non-severe dengue case management, alongside correct antipyretic use and platelet monitoring.
Dr. Rajesh IyerMBBS, MD (Pharmacology)
Clinical Pharmacologist
Dr. Rajesh Iyer is a clinical pharmacologist focusing on drug interactions, adverse-effect profiles, biosimilars, and drug-scheduling regulation in India.